文献速递泌尿男性生殖肿瘤支持与姑息治疗

LATITUDE研究:阿比特龙联合泼尼松对初诊高危转移性去势初治前列腺癌患者报告结局的影响

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-01-08

LATITUDE是一项国际多中心随机3期试验,比较ADT联合阿比特龙+泼尼松与ADT联合安慰剂在初诊高危转移性去势初治前列腺癌患者中的患者报告结局(PRO)和健康相关生活质量(HRQOL)。预设中期分析显示,联合组在疼痛进展、疲劳、功能状态恶化等方面均显著优于对照组,临床获益一致。

核心结论

  • 在初诊高危转移性去势初治前列腺癌患者中,ADT联合阿比特龙+泼尼松相比ADT联合安慰剂,在疼痛进展、前列腺癌症状、疲劳、功能下降和整体HRQOL方面均显示出临床获益。

研究设计与样本

  • 国际多中心随机3期LATITUDE试验,纳入1199例初诊高危转移性去势初治前列腺癌患者,1:1随机分配至ADT联合阿比特龙(1000 mg口服每日一次)+泼尼松(5 mg口服每日一次)组(597例)或ADT联合安慰剂组(602例)。
  • PRO为探索性终点,采用BPI-SF、BFI、FACT-P和EQ-5D-5L量表在电子平板上收集,分析按意向性治疗进行,本次报告为预设第一次中期分析(2016年10月31日)。

临床怎么用

  • 对于初诊高危转移性去势初治前列腺癌患者,ADT联合阿比特龙+泼尼松不仅改善生存,还延缓疼痛、疲劳和功能状态恶化,支持该方案在临床决策中综合考虑PRO获益。

局限性

  • PRO分析为探索性终点,本次报告为预设第一次中期分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study. METHODS: In the multicentre, international, randomised, phase 3 LATITUDE trial, eligible patients were aged 18 years or older, had newly diagnosed, high-risk, metastatic castration-naive prostate cancer confirmed by bone scan (bone metastases) or by CT or MRI (visceral, soft tissue, or nodal metastases), and an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. Patients from 235 clinical sites in 34 countries were randomly assigned (1:1) following a country-by-country scheme done by permuted block randomisation (with two blocks) and stratified by the presence of visceral metastasis and ECOG performance status to receive ADT plus 1000 mg oral abiraterone acetate and 5 mg oral prednisone once daily or ADT plus placebos. Selection of ADT, chemical or surgical, was at the investigator's discretion. The co-primary endpoints of the trial, overall survival and radiographic progression-free survival, have been published. PRO data were collected directly on electronic tablet devices at the clinical sites during screening and before any other visit procedure on day 1 of cycles 1-3, monthly during cycles 4-13, and then every 2 months until the end of treatment, by use of the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy Prostate scale (FACT-P), and the EuroQol (EQ-5D-5L) questionnaires. PRO analyses were an exploratory endpoint. Analyses were by intention-to-treat. Results from the first pre-planned interim analysis (Oct 31, 2016), are presented here. This ongoing study is registered with Clinicaltrials.gov, number NCT01715285. FINDINGS: Between Feb 12, 2013, and Dec 11, 2014, 1199 patients were randomly assigned: 597 to ADT plus abiraterone acetate and prednisone and 602 to ADT plus placebos. Median follow-up was 30·9 months (IQR 21·2-33·2) in the ADT plus abiraterone acetate and prednisone group versus 29·7 months (1·4-43·5; 16·1-31·3) in the ADT plus placebos group. Median time to worst pain intensity progression assessed by the BPI-SF score was not reached in either group (ADT plus abiraterone acetate and prednisone, not reached [95% CI not reached to not reached]; 25th percentile 11·07 months [95% CI 9·23-18·43]; ADT plus placebos group, not reached [95% CI not reached to not reached]; 25th percentile 5·62 [95% CI 4·63-7·39]; hazard ratio [HR] 0·63 [95% CI 0·52-0·77]; p<0·0001). Median time to worst fatigue intensity was not reached in either the ADT plus abiraterone acetate and prednisone group (not reached [95% CI not reached to not reached]; 25th percentile 18·4 months [95% CI 12·9-27·7]) or the ADT plus placebos group (not reached [95% CI not reached to not reached]; 25th percentile 6·5 months [95% CI 5·6-9·2]; HR 0·65 [95% CI 0·53-0·81], p=0·0001). Median time to deterioration of functional status assessed by the FACT-P total score scale was 12·9 months (95% CI 9·0-16·6) in the ADT plus abiraterone acetate and prednisone group versus 8·3 months (7·4-11·1) in the ADT plus placebos group (HR 0·85 [95% CI 0·74-0·99]; p=0·032). INTERPRETATION: The addition of abiraterone acetate plus prednisone to ADT in patients with newly diagnosed, high-risk metastatic castration-naive prostate cancer improved overall PROs by consistently showing a clinical benefit in the progression of pain, prostate cancer symptoms, fatigue, functional decline, and overall HRQOL. FUNDING: Janssen Research & Development.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Chi KN, Protheroe A, Rodríguez-Antolín A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018. PMID: 29326030. doi:10.1016/S1470-2045(17)30911-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。